vaccines-gynecologic-oncology-2018-posters

Page 78

Journal of Clinical Immunology and Allergy

ISSN: 2471-304X

E u r o p e a n C o n g r e s s o n

Vaccines & Vaccination

and Gynecologic Oncology

Vaccines & Vaccination and Gynecologic Oncology 2018

O c t o b e r 2 6 - 2 7 , 2 0 1 8

B u d a p e s t , H u n g a r y

ver the last 250 years, the use of vaccines, a mainstay of preventative medicine and public health mainly in the infectious diseases

area has proven to be one of the most successful and cost-effective medical interventions ever discovered. Despite these great ad-

vances to human and animal health of the past 5 decades; the basic immunologic principals and technology does not work for themost

part against the many remaining pathogens and many cancers of humans and animals. This is mainly due to a combination of evolved

host evading strategies of both infectious pathogens and cancer cells and the yet unappreciated aleatory characteristics inherent

within the vertebrate immune system. These combined make them inherently more capable of outsmarting the host defense systems.

Phenomena such as strain- and serotype-restricted immunity, antigenic variation/mutation, poor anamnestic memory, disease-en-

hancement and incomplete immunity, all are major gaps in our understanding of the complex host evasion mechanisms that have

evolved. Deceptive imprinting is at the heart of a new understanding of how the hosts response to mutable infectious pathogens and

cancer cells to create a molecular diversion (decoy) at the level of both the innate and acquired immune host defense systems, much

like how metallic chaff would confuse a radar system trying to locate a missile or plane. On an immunologic level, immunodominance,

repertoire sculpting and antigenic variation are coupled such that host immune responses are directed to more immunodominant and

non-protective structures resulting non-protective B and T cell immune responses. To circumvent this host evading mechanism, we

have developed a first generation technology called immune refocusing that has been designed specifically to reorder the non-protec-

tive immunodominance by identifying/mapping the decoy epitopes andmolecularly removing or attenuating it thus redirecting the host

immune system to the more protective regions of the microbe. This lecture will bring together those aspects learned from studying

infectious diseases pathogens in new paradigm shifting first principals of deceptive imprinting and immunology and those of cancer

biology in hopes of developing new insights from querying pathogen genomes through pressure point technology and application of

the technology of immune refocusing. These paradigm shifting scientific insights have opened up fresh new approaches to technical

advancement and the development of new antigens that can be used for vaccines and deriving new monoclonal antibodies toward

inducing improved and broader protective immunity for both infectious diseases and cancer.

Immunodominance, deceptive imprinting and

immune refocusing technology: blue print for

deriving next generation biologicals for difficult

microbes

Peter Lloyd Nara

Biological Mimetics Inc., USA

Journal of Clinical Immunology and Allergy, Volume: 4

DOI: 10.21767/2471-304X-C2-006

Euro Vaccines 2018